BioRestorative Therapies, Inc. — Form 8-K
Filed September 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
BioRestorative Therapies completed a 1-for-20 reverse stock split of its common stock, approved by its Board on August 27, 2026, without stockholder vote under Nevada law. Outstanding shares reduced from 27,622,556 to approximately 1,381,128; authorized shares reduced from 1,500,000,000 to 75,000,000. The reverse split aims to restore compliance with Nasdaq's $1.00 minimum bid price rule; trading begins on adjusted basis September 8, 2026.
Why this rating
Reverse split is routine delisting-prevention measure. No economic change to shareholders; ownership percentages and voting power unchanged. Standard corporate governance action relative to company's $11.2M market cap.
See more from September 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.